22 January 2015
Russian pharmaceutical company NovaMedica and Omega Pharma, a Belgium-based pan-European pharmaceutical company specializing in the development and sale of over-the-counter (OTC) health and personal care products, have signed a partnership agreement granting NovaMedica exclusive rights to promote, distribute and sell a line of OTC gastrointestinal products under the BenegastTM umbrella brand in Russia.
Vaccine May Prevent Antibiotic Resistant Skin Infections
11 December 2014
A study reported in the Proceedings of the National Academy of Sciences USA holds new hope for preventing or reducing the severity of infections caused by the “superbug” MRSA. In the study, infectious disease specialists at the Los Angeles Biomedical Research Institute reported that a new investigational vaccine, NDV-3 (licensed to NovaDigm Therapeutics, Inc.), employing the recombinant protein Als3, can mobilize the immune system to fight off MRSA skin infections in an experimental mode.
Medical device makers hope to kill a tax
03 December 2014
The issue has keen interest in Orange County, a hotbed of medical device manufacturing with more than 250 firms employing tens of thousands of people.
Neothetics Files $63M IPO to Advance Drug That Melts “Love Handles”
23 October 2014
A biotech company developing an injectable drug to shrink the excess fat that forms “love handles” says it plans to raise more than $63 million through an IPO.
High Potential for New Products
09 October 2014
NovaMedica is a $760 million joint venture between Rusnano and Domain Associates to develop new drugs in Russia. It's managed by RMI Partners. Anatoly Medetsky spoke to CEO Vladimir Gurdus.
How a U.S. VC firm keeps doing business with Russia
07 October 2014
Around four years ago, a group of U.S. venture capitalists headed to Russia on a state-sponsored trip that was designed to promote foreign investment in the nation’s startups. One of the most impressed VCs was Brian Dovey, a longtime partner with healthcare-focused DomainAssociates. He remained in touch with the Russian organizers, and in Domain later announced a $760 million partnership with Rusnano, a government-owned investment fund in Russia.
Horus Pharma and NovaMedica Sign Agreement to Market a Portfolio of Eye Care Products in Russia
02 October 2014
NovaMedica LLC, a Russian pharmaceutical company, and Horus Pharma SL, a French company dedicated to the development of innovative products treating ophthalmic diseases, have signed a partnership agreement that grants NovaMedica exclusive rights to commercialize a portfolio of products in Russia and the Commonwealth of Independent States (CIS).
Implant means end of reading glasses is in sight
26 August 2014
Scientists have developed a tiny implant, no bigger than a pinhead, which sits inside the cornea and slightly increases its curvature, to allow the eye to focus again.
12 Industry-Venture Fund Alliances: 2014 Edition
01 August 2014
For companies struggling with R&D costs, VC firms can be saviors. It helps to have a friend. And for several pharma giants scrambling to cut R&D costs, those friends are venture capital firms that co-invest in startups whose new drugs and platform technologies appear attractive. In some cases, these pharma-venture “alliances” launch the startups, using the expertise of VC firm partners and company executives. Following is a list of 12 such alliances announced in recent years, mostly by biopharma giants with venture capital firms and alliance between Rusnano and Domain Associates is on the first place by total size of funds.
04 June 2014
NovaMedica’s leader Fabrice Egros told Oksana Baranova, Pharmatsevtichesky Vestnik – Pharmaceutical Bulletin correspondent, about how the expats visualize and estimate prospects of the Russian pharmaceutical market.
05 November 2024
03 November 2024
October 10 – World Mental Health Day
10 October 2024
Siberian State Medical University and Skoltech to start production of bone tissue fillers
22 November 2024
Sechenov University is creating a digital drug reference book
21 November 2024
Skills shortage still holding back pharma's digital transformation: survey
21 November 2024
Trials for Russia’s first CAR-T drug “Utzhefra” have started
20 November 2024